NFKB1 and prostate carcinoma: Treating organoids with SFAs and observing the activation of NF-κB and subsequent changes in cell behavior (such as proliferation, apoptosis, and differentiation) can help understand the impact of SFAs on the tumor microenvironment and the progression of prostate cancer.